# Supplementary Materials



*Figure S1 Proportion of MI patients (age<80) receiving prasugrel by Swedish county councils.*



*Figure S2 Proportion of MI patients (age<80) receiving no P2Y12 inhibitor by Swedish county councils.*



*Figure S3 Proportion of MI patients (age<80) receiving clopidogrel by Swedish county councils.*

Table S1 Definitions of the Value of Eliminating Slow, Low, Delayed and Varying Implementation

|  |  |  |
| --- | --- | --- |
| **Description** | **Area** | **Equation** |
| Population INB |  | $$pINB=\sum\_{t=0}^{T}\frac{I\_{t}}{(1+r)^{t}}ρ\_{t}INB\_{t}$$ |
| **Slow, low and delayed implementation** |
| Population EVPIM  |  | $$pEVPIM=\sum\_{t=0}^{T}\frac{I\_{t}}{(1+r)^{t}}(1-ρ\_{t})INB\_{t}$$ |
| **Eliminating slow implementation**, i.e. implement up to *max*(ρ*t*) from the time when implementation starts (*timplement*) | A | $$pEVSIM\_{A}=\sum\_{t=t\_{implement}}^{T}\frac{I\_{t}}{(1+r)^{t}}(max(ρ\_{t})-ρ\_{t})INB\_{t}$$ |
| **Eliminating low implementation**, i.e. implement in 100%-*max*(ρ*t*) from *timplement* | B | $$pEVSIM\_{B}=\sum\_{t=t\_{implement}}^{T}\frac{I\_{t}}{(1+r)^{t}}(1-max(ρ\_{t}))INB\_{t}$$ |
| **Eliminating implementation delay**, i.e. implement from the time of availability (*t0*) rather than time *timplement* | C | $$pEVSIM\_{C}=\sum\_{t=0}^{t\_{implement}}\frac{I\_{t}}{(1+r)^{t}}INB\_{t}$$ |
| Eliminating implementation delay given actual/expected implementation pattern | C1 | $$pEVSIM\_{C\_{1}}=\sum\_{t=0}^{t\_{implement}}\frac{I\_{t}}{(1+r)^{t}}max(ρ\_{t})INB\_{t}$$ |
| Eliminating implementation delay in 100%-*max*(ρ*t*) | C2 | $$pEVSIM\_{C\_{2}}=\sum\_{t=0}^{t\_{implement}}\frac{I\_{t}}{(1+r)^{t}}(1-max(ρ\_{t}))INB\_{t}$$ |
| **Accounting for regional implementation variation** |
| **Eliminating regional variation in implementation**, i.e. implement in $ρ\_{t}^{hight}$-ρ*t* from *timplement* | D | $$pEVSIM\_{D}=\sum\_{t=t\_{implement}}^{T}\frac{I\_{t}}{\left(1+r\right)^{t}}(ρ\_{t}^{high}-ρ\_{t})INB\_{t}$$ |
| Eliminating slow implementation compared to implementation in highest implementing region, i.e. implement in *max*($ρ\_{t}^{hight}$)-($ ρ\_{t}^{hight}$) from timplement | E | $$pEVSIM\_{E}=\sum\_{t=t\_{implement}}^{T}\frac{I\_{t}}{\left(1+r\right)^{t}}(max\left(ρ\_{t}^{high}\right)-ρ\_{t}^{high})INB\_{t}$$ |
| Eliminating low implementation compared to highest observed implementation level, i.e. implemented in 100%-*max*($ρ\_{t}^{hight}$) from timplement | F | $$pEVSIM\_{F}=\sum\_{t=t\_{implement}}^{T}\frac{I\_{t}}{\left(1+r\right)^{t}}(1-max\left(ρ\_{t}^{high}\right))INB\_{t}$$ |
| Eliminating implementation delay given implementation pattern in the highest implementing region  | C2a | $$pEVSIM\_{C\_{2a}}=\sum\_{t=0}^{t\_{implement}}\frac{I\_{t}}{\left(1+r\right)^{t}}(max\left(ρ\_{t}^{high}\right)-max\left(ρ\_{t}\right))INB\_{t}$$ |
| Eliminating implementation delay in 100%-*max*($ρ\_{t}^{hight}$) | C2b | $$pEVSIM\_{C\_{2a}}=\sum\_{t=0}^{t\_{implement}}\frac{I\_{t}}{(1+r)^{t}}(1-max\left(ρ\_{t}^{high}\right))INB\_{t}$$ |
| INB*t*is the expected incremental net benefit defined as the expectation over some uncertain parameters θ (EθINB(θ)) at time t, which can be estimated in terms of incremental net health benefit (INHB) or incremental net monetary benefit (INMB): $INHB=∆E-∆C/λ; INMB=∆E\*λ-∆C$, where ΔE and ΔC is the incremental effect and cost, respectively, and λ is the cost-effectiveness threshold$I\_{t}$ total number of eligible patients in time period t*r* is the discount rateρ*t*is the actual/expected level of implementation in time period t*max*(ρ*t*) is the highest (average) level of implementation observed across all time periods$ρ\_{t}^{high}$ is the implementation level in the **highest implementing region** at time t*max*($ρ\_{t}^{high}$) is the highest level of implementation observed in any region across all time periods *T* is the time at which the intervention loses relevance*t0* is the time when the technology becomes available for use *timplement*is the time at where implementation starts |